Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO.

"Declarations Ethics approval and consent to participateFor both ADNI and MEMENTO, ethics approval was obtained from the review boards of the participating institutions. Informed consent was obtained from every participant prior to enrollment. Consent for publicationAll authors have approved the contents of this manuscript and provided consent for publication. Competing interestsHC, RL, SN, PR report no conflicts. ES has received consulting fees from Eli Lilly. ZI has received consulting fees from Otsuka/Lundbeck, outside the submitted work. His institution has received funds from Biogen and Roche, also outside the submitted work. Competing interests HC, RL, SN, PR report no conflicts. ES has received consulting fees from Eli Lilly. ZI has received consulting fees from Otsuka/Lundbeck, outside the submitted work. His institution has received funds from Biogen and Roche, also outside the submitted work."

"Funding This work was also supported by CIC1401-EC, Bordeaux University Hospital (CHU Bordeaux, sponsor of the cohort), Inserm, and the University of Bordeaux. The MEMENTO cohort has received funding support from FUJIREBIO through private–public partnerships. ZI is funded by a grant from the Canadian Institutes for Health Research (BCA 2633). ZI, BC, and CB are supported by the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care."